Michele Liuzzi

Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA.

Institut Pasteur Korea Research Foundation provides research and development for the treatment of infectious and chronic diseases. It develops a technology-based approach to therapeutic development through cellular models, high content screening and medicinal chemistry. The company was founded on December 29, 2003 and is headquartered in Seongnam, South Korea.

Boehringer Ingelheim (Canada) Ltd. engages in the research and development of new drugs and medicines for the treatment of respiratory diseases. The firm offers therapeutic options for diseases and conditions, such as chronic obstructive pulmonary disease, high blood pressure, stroke, depression, benign prostatic hyperplasia, Parkinson's disease, virology, stroke prevention in atrial fibrillation, and diabetes. The company was founded in 1972 and is headquartered in Burlington, Canada.